IGF2R and metabolic syndrome: A recent study showed significantly elevated levels of circulating miR-143-3p in patients with metabolic syndrome, which, when inhibited in a mouse model, inhibited insulin resistance (IR), and its key target was insulin-like growth factor 2 receptor [16].